On January 16, 2026, Exicure, Inc. (the "Company") reported the first contractual milestone under its License and Collaboration Agreement (the "Agreement") with GPCR Therapeutics Inc. The milestone relates to the completion of the Company’s Phase 2 clinical trial of its novel stem cell mobilizer (NCT05561751), which was achieved through the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026. Under the terms of the Agreement, the Company is required to make a milestone payment of $1,000,000 to GPCR Therapeutics Inc. within 30 days of achieving this milestone. The Company intends to make this payment in accordance with the terms of the Agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company believes that achieving this milestone reflects continued progress in the development and advancement of the small molecule CXCR4 inhibitor, Burixafor (GPC‑100). In addition, under the terms of the Agreement, completion of this milestone triggers the future sublicensing income‑sharing ratio, reflecting the Company’s increased participation in and commitment to the long‑term success of the program.

(Press release, Exicure, JAN 16, 2026, View Source [SID1234662165])